| 词条 | Sangamo Therapeutics |
| 释义 |
| name = Sangamo Therapeutics | logo = Sangamo Therapeutics.png | type = Public | traded_as = {{NASDAQ|SGMO}} Russell 2000 Index component | industry = Biotechnology | founded = 1995 | founders = | location_city = Brisbane, California, U.S. | key_people = Sandy Macrae (CEO) Edward Rebar (CTO) | products = | num_employees = 182 | website = {{URL|sangamo.com}} }}Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc.) is an American biotechnology company based in Richmond, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.[1] HistoryThe company was founded in 1995 in Richmond, California.[2] It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. In September 2018, it had 182 employees.[2] Sandy Macrae is the president.[3] In 2018, Edward Rebar became the senior vice president and chief technology officer of Sangamo.[4] ResearchSangamo applies technology to treat haemophilia B and lysosomal storage diseases including mucopolysaccharidosis type I (Hurler Syndrome) and mucopolysaccharidosis type II (Hunter Syndrome). The FDA granted Sangamo fast track designation for SB-525, a gene therapy candidate for haemophilia A. In its partnership with Pfizer, Sangamo uses Bioverativ in hemoglobinopathies such as beta thalassemia and sickle cell disease.[1] It is also developing zinc finger gene editing technology.[5] In February 2019, medical scientists, working with Sangamo Therapeutics, announced the first ever "in body" human gene editing therapy to permanently alter DNA - in a patient with Hunter Syndrome.[6] Clinical trials by Sangamo involving gene editing using Zinc Finger Nuclease (ZFN) are ongoing.[7] References1. ^1 {{Cite news|url=https://pharmaphorum.com/news/sangamo-new-gene-therapy-partner-pfizer-lifted-fda-fast-track/|title=Sangamo and new gene therapy partner Pfizer lifted by FDA fast track|last=McConaghie|first=Andrew|date=2017-05-17|work=Pharmaphorum|access-date=2018-10-01|language=en-GB}} 2. ^1 {{Cite news|url=https://www.equities.com/news/sangamo-therapeutics-inc-sgmo-moves-higher-on-volume-spike-for-september-04|title=Sangamo Therapeutics Inc. (SGMO) Moves Higher on Volume Spike for September 04|last=|first=|date=2018-09-08|work=Equities|access-date=2018-10-01|language=en-US}} 3. ^{{Cite journal|last=Ledford|first=Heidi|date=2018-09-05|title=First test of in-body gene editing shows promise|url=http://www.nature.com/articles/d41586-018-06195-6|journal=Nature|language=EN|doi=10.1038/d41586-018-06195-6|issn=0028-0836}} 4. ^{{Cite web|url=http://www.poandpo.com/who-is-promoted/sangamo-therapeutics-appoints-edward-rebar-as-senior-vice-president--1672018988/|title=Sangamo Therapeutics appoints Edward Rebar as senior vice president|last=|first=|date=2018-07-16|website=Post Online Media|location=Richmond, California|language=en|archive-url=|archive-date=|dead-url=|access-date=2018-10-01}} 5. ^{{Cite news|url=https://www.fool.com/investing/2018/09/06/sangamos-zinc-fingers-fail-again-time-to-walk-away.aspx|title=Sangamo's Zinc Fingers Fail Again. Time to Walk Away?|last=Renauer|first=Cory|date=2018-09-06|work=The Motley Fool|access-date=2018-10-01|language=en}} 6. ^{{cite news |last=Marchione |first=Marilyn |title=Tests suggest scientists achieved 1st ‘in body’ gene editing |url=https://www.apnews.com/d728f86d70d94ce68dd4fedffe58d03f |date=7 February 2019 |work=AP News |accessdate=7 February 2019 }} 7. ^{{cite web |author=Staff |title=Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II |url=https://clinicaltrials.gov/ct2/show/NCT03041324 |date=2 February 2019 |website=ClinicalTrials.gov |publisher=U.S. National Library of Medicine |access-date=7 February 2019}} External links
| name = Sangamo Therapeutics | symbol = SGMO | sec_cik = SGMO | yahoo = SGMO | google = SGMO }}{{Portal bar|Companies|Biotechnology}}{{coord missing|Contra Costa County, California}}{{Authority control}}{{DEFAULTSORT:Sangamo Therapeutics}} 6 : Companies based in Richmond, California|Biotechnology companies of the United States|1995 establishments in California|Orphan drug companies|Biotechnology companies established in 1995|Health care companies based in California |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。